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Abstract
Bac kground: Early diagnosis of Alzheimer’s disease (AD) may 
be corroborated by imaging of beta-amyloid plaques using 
positron emission tomography (PET). Here, we performed 
an add-on questionnaire study to evaluate the relevance of 
florbetaben imaging (BAY 94-9172) in diagnosis and con-
secutive management of probable AD patients. Methods: 
AD patients with a clinical diagnosis in accordance with 
the NINCDS-ADRDA criteria or controls were imaged using 
 florbetaben. Referring physicians were asked on a voluntary 
basis about their confidence in initial diagnosis, significance 
of PET imaging results, and their anticipated consequences 
for future patient care. Results: 121 questionnaires for prob-
able AD patients and 80 questionnaires for controls were 
evaluated. In 18% of patients who had initially received the 
diagnosis of probable AD, PET scans were rated negative, 
whereas in controls 18% of scans were positive. An increase 
in confidence in the initial diagnosis was frequently report-
ed (80%). Imaging results had a significant impact on the in-
tended patient care, as judged by the referring physicians; 
this was most prominent in those patients with a contra-
dicting scan and/or a low confidence in the initial diagno-
sis. Conclusion: Florbetaben amyloid imaging increases the 
overall confidence in diagnosis of AD and may frequently 
influence clinical decisions and patient management.
 Copyright © 2012 S. Karger AG, Basel
Introduction
Biomarkers that support early diagnosis of Alzheimer’s 
disease (AD) are useful in the differential diagnosis and 
urgently needed in disease-modifying therapeutic strate-
gies and longitudinal monitoring of disease progression. 
A pivotal problem in early diagnosis of AD is that clini-
cal symptoms as assessed by neuropsychological tests 
become apparent only after massive neuronal cell loss 
has already taken place. Today, there is general agree-
ment that diagnosis of AD should be based on the results 
of various neuropsychological tests [1], brain imaging 
[2–4], cerebrospinal fluid (CSF) and blood studies [5–7], 
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the patient’s own and family history, and a physical ex-
amination. Recently, revised guidelines for the clinical 
diagnosis of AD have been proposed by the National 
Institute on Aging and the Alzheimer’s Association [8]. 
These guidelines add altered biomarkers as a criterion to 
enhance the likelihood of underlying AD pathology in 
the diagnosis of probable AD. Additionally, since a num-
ber of disease-modifying therapies like vaccination and 
immune-modulating strategies are under investigation 
[9], better diagnostic tools within the biomarker field will 
be valued.
An ideal biomarker reliably reflects important pro-
cesses of the underlying disease pathology. In AD, certain 
biomarkers become abnormal, presumably in a tempo-
rally ordered manner. According to a recently published 
model, at the earliest stage of AD, changes in CSF beta-
amyloid appear first, reaching a plateau by the time clini-
cal symptoms emerge [10]. Consecutively, an increase in 
biomarkers reflecting neuronal injury such as total- and 
phospho-Tau protein may be followed by first clinical 
symptoms. To date, beta-amyloid and Tau protein can be 
determined in the CSF using different techniques [11], 
but results may be sometimes difficult to interpret. CSF 
biomarker levels may be weighted by sources of error: 
Amyloid-beta 1-42 and total-Tau protein levels vary up 
to 3-fold in different studies [12, 13]. In addition, con-
centrations may differ depending on the modalities of 
lumbar puncture, such as time of day and amount of CSF 
taken [14].
Recently, compounds which can be used in positron 
emission tomography (PET) to directly visualize beta-
amyloid plaques within the human brain have come into 
focus as a tool to improve diagnosis of AD. The Pittsburgh 
compound B (PIB), an analog of thioflavin T, represents 
the most widely used tracer for investigational PET im-
aging of beta-amyloid plaques in the brain. Retention 
of the 11C-labeled PiB ([C-11]PiB) has been shown to 
be approximately 2-fold greater in cortical areas of AD 
subjects relative to healthy controls, and the patterns of 
retention reflect the patterns of beta-amyloid deposition 
known from postmortem studies [15]. Florbetaben, an 
18F-labeled tracer utilizing a radioisotope with a longer 
half-life than PIB [16, 17] is currently being tested in a 
phase III clinical trial program.
Here, we report on a study to address the question 
how in a clinical setting the information of results from 
amyloid-PET imaging in patients with possible or prob-
able AD would influence diagnostic reevaluations of 
physicians, their choice of treatment options and their 
intended general patient management.
Methods
Participants
Between February 2010 and March 2011, a question-
naire study was conducted as an add-on to the multicenter 
beta-amy loid-specific florbetaben PET phase IIb trial with 
a total of 272 patients (demographic data in online suppl. 
table 1; for all online suppl. material, see www.karger.com/
doi/10.1159/000339367). Study participants were either pa-
tients diagnosed with probable AD or healthy volunteers that 
were directly recruited as unimpaired controls from the com-
munity. The lack of cognitive impairment in healthy volunteers 
was based on an MMSE result ≥28 and a CDR of 0. Patients 
with probable AD had to fulfill both the DSM-IV criteria for 
dementia of AD and the NINCDS-ADRDA criteria for AD. 
The MMSE score had to be between 18 and 26 and the CDR 0.5, 
1.0 or 2.0. Duration and history of the disease varied between 
probable AD patients. CSF biomarker values were only avail-
able for a small subset of patients, were not part of the study 
protocol, and were not further evaluated. For both groups, the 
diagnosis had been affirmed by magnetic resonance brain im-
aging before admission to PET scan.
The questionnaire was given to referring physicians in 
Australia, Germany, Japan, Switzerland, and USA whose pa-
tients received florbetaben PET imaging in the context of the 
phase IIb trial. Fourteen out of a total of 20 centers participated 
on a voluntary basis. A total of 201 questionnaires were com-
pleted and sent back to the authors (supplementary table 2).
Table 1. Correlation between the degree of confidence in the ini-
tial diagnosis and the level of impact on management of probable 
AD patients
Degree of confidence in
preexisting diagnosis
Level of impact on patient 
management
str ong +
some
minor +
none
total
Very high
 Probable AD patients 25 33 058
 Confirming scan 24 30 054
 Contradicting scan 01 03 004
Moderate + low
 Probable AD patients 50 13 063
 Confirming scan 33 12 045
 Contradicting scan 17 01 018
Sum
 Probable AD patients 75 46 121
 Confirming scan 57 42 099
 Contradicting scan 18 04 022
Fisher exact test (d.f. = 1). Probable AD patients: χ2 15.35; p 
value 0.00009; odds ratio 0.20, CI95 0.09–0.44. Confirming scans: 
χ2 7.25; p value 0.007; odds ratio 0.29, CI95 0.12–0.68. Contradict-
ing scans: χ2 6.45; p value 0.011; odds ratio 0.02, CI95 0.00–0.41.
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Procedure
A face-validated, ‘fit-for-purpose’ clinician questionnaire 
was designed, consisting of six items evaluating (1) the level of 
confidence in the initial clinical diagnosis before PET imaging 
results were known, (2) the objective results of the florbeta-
ben PET scan, (3) the congruency of the PET imaging and the 
initial diagnosis, (4) the potential change of confidence in the 
overall diagnosis on the basis of the PET scan results, (5) the 
importance, and (6) the characteristics of the potential impact 
on patient management. For the original questionnaire, please 
refer to the supplementary material.
The questionnaire was validated in advance for clarity and 
appropriateness by clinical physicians. The questionnaires 
were completed by the clinical centers that were referring pa-
tients to the respective nuclear medicine departments. The re-
turned questionnaires had been fully anonymized.
Statistical Analysis
For statistical analysis, SAS version 9.1 was used. Results 
are expressed as number (%) or means ± SD unless indicated 
otherwise. Frequency distributions for categorical variables 
(see fig. 4) were compared using the Fisher exact test (table 
1).
Homogeneity of the participating centers (table 2) was ana-
lyzed using the Cochran-Mantel-Haenszel test stratifying for 
centers. The variables collected were dichotomized as follows: 
the item ‘confidence in diagnosis before PET scan’ into ‘high 
confidence’ and ‘moderate + weak + very weak confidence’; the 
item ‘change of confidence in diagnosis after PET scan’ into ‘in-
creased + decreased confidence’ and ‘unchanged confidence’; 
the item ‘impact on patient management after PET scan’ into 
‘strong + some impact’ and ‘minor + no impact’.
Results
Fourteen out of the 20 centers participating in the flo-
rbetaben phase IIb clinical trial returned 201 question-
naires (74% response rate): 121 referred to probable AD 
patients and 80 to unimpaired controls. Among the 121 
probable AD patients, 22 (18%) patients showed no sig-
nificant beta-amyloid plaque load as examined using the 
onsite beta-amyloid plaque load visual assessment score 
[17]. On the other hand, 18% (n = 14 out of 80) of the 
controls presented with a significant plaque load as as-
sessed by the onsite nuclear physician (fig. 1).
After Knowledge of PET Outcome, Change of 
Confidence in Diagnosis Is Common
Focusing on AD patients, we were interested to learn 
whether the results of the beta-amyloid-specific PET 
scan lead to a change of diagnostic confidence. The over-
all change of confidence in the initial diagnosis after 
receiving the PET scan results was common: in 83% of 
all probable AD cases, a change of confidence, either an 
increase or a decrease, in the original diagnosis was re-
ported (n = 22 + 77 + 2 = 101 of 121; black and light 
Table 2. Analysis of homogeneity amongst the 14 participating 
centers
Questionnaire item and group Value of the
test statistic
p
value
Confidence in diagnosis before PET scan
AD, all results 08.5693 0.0034
AD, negative scan result 00.6341 0.4259
AD, positive scan result 10.5393 0.0012
UC, all results 03.5680 0.0589
UC, negative scan result 12.3381 0.0004
UC, positive scan result 02.3257 0.1273
Change of confidence in diagnosis after PET scan
AD, all results 08.0577 0.0028
AD, negative scan result 0n.v. n.v.
AD, positive scan result 08.2022 0.0042
UC, all results 00.2456 0.6202
UC, negative scan result 02.5937 0.1073
UC, positive scan result 10.5670 0.0012
Impact on patient management after PET scan
AD, all results 00.0248 0.8748
AD, negative scan result 01.9050 0.1675
AD, positive scan result 00.0237 0.8776
UC, all results 00.1591 0.6899
UC, negative scan result 09.2785 0.0023
UC, positive scan result 07.3014 0.0069
Cochran-Mantel-Haenszel test; p < 0.05, indicative of hetero-
geneity; p > 0.05, not indicative of heterogeneity; AD = probable 
AD patients; UC = unimpaired controls; n.v. = no variability.
 Fig. 1. Frequency of positive and negative florbetaben PET scan 
results. Numbers are given for patients with the clinical diagnosis 
of probable AD and for unimpaired controls.
66 (82%)
80
Unimpaired
controls 121
Probable
AD patients
14
22
99 (82%)
Negative PET scan
Positive PET scan
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grey areas, fig. 2). In all probable AD cases with a nega-
tive PET scan (n = 22), physicians reported a decrease in 
confidence in their original diagnosis (fig. 2). In prob-
able AD cases with an expected positive PET scan result, 
the physicians indicate in 78% of the cases an increase (n 
= 77), in 2% a decrease (n = 2; reportedly due to lower 
signal intensities in the PET scans than expected by the 
physicians), and in 20% no change of confidence in their 
initial diagnosis (n = 20).
Even in the group of controls, a change of confidence 
in the initial clinical evaluation was reported in 43% of all 
the cases (n = 34 out of 80; data not shown). Within the 
group of controls with an unexpected positive scan, 10 
out of 14 cases (71%) reported a decrease in confidence 
in the original diagnosis; within the group of controls 
with an expected negative scan, 24 out of 66 cases (36%) 
reported an increase in confidence.
Physicians Anticipate Impact on Patient Management
In a second step, we aimed to determine whether 
the results of the PET scan could have an influence on 
patient management. Overall, physicians reported an 
anticipated impact on their patient management of prob-
able AD patients in 89% of the cases (n = 108 out of 121) 
and in 35% of the controls (n = 28 out of 80). Regarding 
the impact level (strong, some, minor, no impact), we 
detected a wide range (n = 35 vs. 40 vs. 33 vs. 13 cases, 
respectively; fig. 3), and in about 2 out of 3 probable AD 
patients either a strong or some impact. In controls, this 
distribution was more pronounced (n = 1 vs. 17 vs. 10 vs. 
52 cases, respectively; not shown). The actual measures 
and changes in patient management at a later time point 
were not evaluated within this study.
When further dissecting the characteristics of the im-
pact in cases of probable AD, we frequently found for 
‘strong impact’ and ‘some impact’ a relevance regarding 
the intended treatment or alternative diagnostic options 
(fig. 3, black and dark grey areas). The term ‘defined 
other impact’ in strong, some and minor impact cat-
egories includes ‘reassurance to continue the preexisting 
treatment’, ‘recommendations for a modified lifestyle’, 
‘change in communication with the patient’, and occa-
sionally ‘validation for inclusion into a vaccination trial’ 
(fig. 3, light grey areas). A minor impact with no further 
specification was reported in 13 patients (fig. 3, white 
area in the column ‘minor’).
Level of Impact Correlates with Degree of Confidence 
in NINCDS-ADRDA-Based Diagnosis
To understand what renders results of amyloid-specif-
ic PET scans having a potentially high or a low clinical 
impact, we tested for a possible correlation between the 
degree of impact and the level of confidence in the origi-
Fig. 2. Frequency and direction of change of confidence in the 
initial diagnosis on receiving the result of the florbetaben PET 
scan. Numbers are given for the 121 probable AD patients.
22
Negative
scan
Positive scan
99
20
2
77 (78%)
22
(100%)
Confidence decreased
Confidence increased
Confidence unchanged
Fig. 3. Level and type of impact on patient management in prob-
able AD patients. For the 121 probable AD patients, the frequency 
of strong, some, minor, and no impact reported by the physicians 
is depicted in the four columns. The various shades of the col-
umns indicate the type of impact. Note that although all these 
patients had been diagnosed with probable AD before receiving 
a PET scan for beta-amyloid, there is a remarkable number of pa-
tients with a significant impact reported.
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nal diagnosis of all probable AD cases. In this analysis, we 
dichotomized the categories impact and confidence and 
merged the answers ‘strong impact/some impact’, ‘minor 
impact/no impact’, and ‘moderate confidence/low con-
fidence’. The frequencies of cases in the resulting three 
categories and the fourth category ‘very high confidence’ 
were compiled in a 2 × 2 contingency table as shown in 
figure 4. Considering the subgroups of confirming and 
contradicting PET scan results, we found a significant 
correlation using the Fisher exact test (table 1). The level 
of the anticipated impact is profoundly influenced by the 
degree of confidence in the preexisting diagnosis. This 
correlation is strongest in the group of preexisting AD 
diagnosis with a contradicting, negative, PET scan result 
(odds ratio 0.02; p value 0.011). Moreover, this effect can 
also be observed in probable AD cases where the initial 
diagnosis was confirmed by the PET scan result (odds 
ratio 0.29; p value 0.007).
Analysis of Consistency in Reporting
To test whether the participating physicians show cen-
ter-specific variability in their judgments, we performed 
a statistical analysis of the homogeneity of their report-
ing to the questions about (1) the degree of confidence in 
original diagnosis, (2) the change of confidence in origi-
nal diagnosis, and (3) the impact on patient management 
after PET scan results have been communicated (table 2). 
For reasons of simplicity, we combined the two catego-
ries ‘decrease in confidence/increase in confidence’ into a 
single category ‘change of confidence’.
The 14 participating centers were only in partial 
agreement with regard to the diagnostic and therapeutic 
potential of amyloid imaging. Most physicians reported 
a change of confidence in their initial diagnosis when 
receiving a contradicting, negative, PET scan result. The 
physicians, however, varied with respect to their inclina-
tion to report a change of confidence in their original 
diagnosis when receiving positive PET results, both for 
probable AD patients and for controls. No significant 
variability amongst the centers was found for the esti-
mated impact on patient management, irrespective of 
whether the PET scan results were substantiating or con-
tradicting the initial diagnosis.
Discussion
Within the past decade, amyloid imaging was more or 
less restricted to highly specialized research centers be-
cause the only available tracer, the Pittsburg compound 
(PIB), contains the short-lived 11-carbon nuclide which 
has to be produced with a cyclotron onsite. With the ad-
vent of 18-fluorine-based tracers with longer half-lives 
amyloid-imaging will become more broadly available 
within the next years, and will potentially constitute an 
essential part of routine diagnostic procedures in AD.
Therefore, we here evaluated the impact and useful-
ness of beta-amyloid-specific PET imaging using the 
18F-labelled tracer florbetaben [16]. Physicians were 
asked about their confidence in clinical diagnosis before 
and after the PET results were known. Our analysis fo-
cuses on the evaluation of probable AD cases, since the 
use of beta-amyloid PET imaging in controls presently 
does not reflect clinical routine.
Florbetaben PET Contributes to the Overall 
Confidence in Clinical Diagnosis
The added value of beta-amyloid-specific PET scans 
within the clinical routine of physicians has not been as-
sessed so far. Not surprisingly, negative PET scans show-
ing no amyloid burden in demented patients classified 
in advance as probable AD by DSM-IV and NINCDS-
ADRDA criteria, resulted in a decreased confidence in 
the original diagnosis in all cases. However, in as many 
as 80% of probable AD cases when diagnosis was con-
firmed by a positive PET scan, results were also judged to 
change the confidence in the initial diagnosis. This high 
percentage appears unexpected, especially if one takes 
into account that the evaluation was conducted in spe-
cialized centers well familiar with the clinical diagnosis 
of AD. This finding might reflect the uncertainty of non-
biomarker NINCDS-ADRDA criteria-based AD diagno-
Fig. 4. Confidence in the initial diagnosis versus impact on pa-
tient management in the 121 probable AD patients. The numerics 
in the contingency table represent the numbers of the combined 
groups. The numbers in italics represent the sums across the re-
spective rows and columns. Refer to table 1 for statistical analysis.
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sis and indicate the added value of the amyloid-specific 
PET scan as a method to directly visualize a patient’s am-
yloid burden in vivo.
Anticipated Treatment Regime Changes with 
Confidence in the Diagnosis
One might argue that a change, i.e. a decrease or in-
crease, of confidence in the original diagnosis has no 
added value for clinical physicians per se and will espe-
cially not have further implications in terms of treatment 
options. Our data, however, indicate that the intended 
treatment regime apparently changes for probable AD pa-
tients. Possible changes that were described included con-
tinuation of antidementive treatment, recommendation 
of lifestyle changes (i.e. increase in physical and social ac-
tivity, etc.), and altered communication with the patient, 
all most likely reflecting a stronger confidence of the phy-
sicians in their actions. This might in turn contribute to a 
higher acceptance of and adherence to the recommended 
treatment amongst patients and their relatives.
In this respect, the benefit is rated highest for those 
cases where physicians have substantial doubts in their 
initial diagnosis. As this likely includes patients at early 
stages of their disease, one can hypothesize that they 
would benefit from an earlier start of drug treatment. 
Further, the increased confidence in diagnosis could also 
influence the communication and reassurance between 
specialist physician and primary care physician who cares 
for the patient in an outpatient/routine setting. Also, on 
the basis of the PET scan results, some patients of this 
study might have been included in ongoing clinical tri-
als with beta-amyloid antibodies or other potentially 
disease-modifying drugs. This reflects another aspect 
and particular value, since a better diagnosis in terms of a 
quantifiable biomarker means a more meaningful evalu-
ation of the treatment options [18]. CSF biomarker anal-
ysis was performed only in a subset of patients and was 
not part of the study protocol. The envisaged correlation 
of the PET scan and CSF biomarker results will further 
define the value of different diagnostic methods.
Negative PET Scans in Probable AD Prompting 
Further Investigation
Our study shows negative PET scans in 18% of the 
probable AD cases that had been identified by applying the 
DSM-IV and the NINCDS-ADRDA criteria. This could 
be interpreted as a limitation of the clinical assessment 
on the basis of which the AD patients have been identi-
fied and included in the phase IIb study [16]. Postmortem 
neuropathological examination which is now underway 
for florbetaben in a phase III trial may clarify whether this 
interpretation reflects reality. To date, the correspondence 
of the florbetaben PET signal to the beta-amyloid plaque 
burden in the brain has not been described. But, the cor-
relation of amyloid beta aggregates in frontal cortical bi-
opsy specimen to a higher uptake of the PET tracer [11C]
PiB has clearly been demonstrated [19].
As to the 18% positive PET scans in the unimpaired 
controls, it is almost certain that these individuals while 
having already beta-amyloid deposits in their brain do 
not, or not yet, suffer from cognitive deficits, which is in 
line with the temporal cascade concept recently reviewed 
[10]. Furthermore, studies that compare postmortem 
histopathological analyses with results of PET scans per-
formed with the beta-amyloid tracer PiB did not yield 
any false-positive results [20].
Taken together, this questionnaire study shows that 
AD diagnosis supported by florbetaben PET imaging 
may increase confidence of clinicians and may influ-
ence patient management. In the context of the recently 
revised guidelines for the clinical diagnosis of AD [8], 
which for the first time incorporate altered biomarkers 
of the underlying disease state as a supportive criterion 
for the diagnosis AD, the push for a stronger focus on 
biomarkers in the diagnosis of AD is evident.
Acknowledgements
We thank all coworkers in the participating centers. Also, 
we would like to thank all patients, their caregivers, and the 
healthy volunteers who participated in this study.
References 
 1 Wagner M, Wolf S, Reischies FM, Daerr M, 
Wolfsgruber S, Jessen F, Popp J, Maier W, 
Hull M, Frolich L, Hampel H, Perneczky 
R, Peters O, Jahn H, Luckhaus C, Gertz HJ, 
Schroder J, Pantel J, Lewczuk P, Kornhuber J, 
Wiltfang J: Biomarker validation of a cued re-
call memory deficit in prodromal Alzheimer 
disease. Neurology 2012;78:379–386.
 2 Degerman Gunnarsson M, Lindau M, Wall 
A, Blennow K, Darreh-Shori T, Basu S, Nor-
dberg A, Larsson A, Lannfelt L, Basun H, 
Kilander L: Pittsburgh compound-B and Al-
zheimer’s disease biomarkers in CSF, plasma 
and urine: an exploratory study. Dement 
Geriatr Cogn Disord 2010;29:204–212.
 3 Blennow K, Vanmechelen E: Combination 
of the different biological markers for in-
creasing specificity of in vivo Alzheimer’s 
testing. J Neural Transm Suppl 1998;53:
223–235.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
21
/2
01
6 
5:
51
:1
7 
PM
Dement Geriatr Cogn Disord 2012;33:416–422422 Schipke et al.
 4 Teipel SJ, Peters O, Heuser I, Jessen F, Maier 
W, Froelich L, Arlt S, Hull M, Gertz HJ, Ko-
rnhuber J, Wiltfang J, Thome J, Rienhoff O, 
Meindl T, Hampel H, Grothe M: Atrophy 
outcomes in multicentre clinical trials on Al-
zheimer’s disease: effect of different process-
ing and analysis approaches on sample sizes. 
World J Biol Psychiatry 2011;12(suppl 1):
109–113.
 5 Lewczuk P, Esselmann H, Bibl M, Beck G, 
Maler JM, Otto M, Kornhuber J, Wiltfang 
J: Tau protein phosphorylated at threonine 
181 in CSF as a neurochemical biomarker in 
Alzheimer’s disease: original data and review 
of the literature. J Mol Neurosci 2004;23:
115–122.
 6 Lewczuk P, Kamrowski-Kruck H, Peters O, 
Heuser I, Jessen F, Popp J, Burger K, Ham-
pel H, Frolich L, Wolf S, Prinz B, Jahn H, 
Luckhaus C, Perneczky R, Hull M, Schroder 
J, Kessler H, Pantel J, Gertz HJ, Klafki HW, 
Kolsch H, Reulbach U, Esselmann H, Maler 
JM, Bibl M, Kornhuber J, Wiltfang J: Soluble 
amyloid precursor proteins in the cerebro-
spinal fluid as novel potential biomarkers of 
Alzheimer’s disease: a multicenter study. Mol 
Psychiatry 2010;15:138–145.
 7 Schipke CG, Jessen F, Teipel S, Luckhaus C, 
Wiltfang J, Esselmann H, Frolich L, Maier 
W, Ruther E, Heppner FL, Prokop S, Heuser 
I, Peters O: Long-term stability of Alzheim-
er’s disease biomarker proteins in cere-
brospinal fluid. J Alzheimers Dis 2011;26:
255–262.
 8 Jack CR Jr, Albert MS, Knopman DS, McK-
hann GM, Sperling RA, Carrillo MC, Thies 
B, Phelps CH: Introduction to the recom-
mendations from the National Institute on 
Aging-Alzheimer’s Association workgroups 
on diagnostic guidelines for Alzheimer’s dis-
ease. Alzheimers Dement 2011;7:257–262.
 9 Blennow K, Hampel H, Weiner M, Zetterberg 
H: Cerebrospinal fluid and plasma biomark-
ers in Alzheimer disease. Nat Rev Neurol 
2010;6:131–144.
10 Jack CR Jr, Knopman DS, Jagust WJ, Shaw 
LM, Aisen PS, Weiner MW, Petersen RC, 
Trojanowski JQ: Hypothetical model of 
dynamic biomarkers of the Alzheimer’s 
pathological cascade. Lancet Neurol 2010;9:
119–128.
11 Schipke CG, Prokop S, Heppner FL, Heuser 
I, Peters O: Comparison of immunosorbent 
assays for the quantification of biomarkers 
for Alzheimer’s disease in human cerebrospi-
nal fluid. Dement Geriatr Cogn Disord 2011;
31:139–145.
12 Shaw LM, Vanderstichele H, Knapik-Czajka 
M, Clark CM, Aisen PS, Petersen RC, Blen-
now K, Soares H, Simon A, Lewczuk P, 
Dean R, Siemers E, Potter W, Lee VM, Tro-
janowski JQ: Cerebrospinal fluid biomarker 
signature in Alzheimer’s disease neuroimag-
ing initiative subjects. Ann Neurol 2009;65:
403–413.
13 Mattsson N, Andreasson U, Persson S, Arai 
H, et al: The Alzheimer’s Association exter-
nal quality control program for cerebrospinal 
fluid biomarkers. Alzheimers Dement 2011;
7:386–395.e386.
14 Schoonenboom NS, Mulder C, Vander-
stichele H, Van Elk EJ, Kok A, Van Kamp GJ, 
Scheltens P, Blankenstein MA: Effects of pro-
cessing and storage conditions on amyloid 
beta (1–42) and tau concentrations in cere-
brospinal fluid: implications for use in clini-
cal practice. Clin Chem 2005;51:189–195.
15 Wang Y, Klunk WE, Debnath ML, Huang 
GF, Holt DP, Shao L, Mathis CA: Develop-
ment of a PET/SPECT agent for amyloid im-
aging in Alzheimer’s disease. J Mol Neurosci 
2004;24:55–62.
16 Barthel H, Gertz HJ, Dresel S, Peters O, 
Bartenstein P, Buerger K, Hiemeyer F, 
Wittemer-Rump SM, Seibyl J, Reininger C, 
Sabri O: Cerebral amyloid-beta PET with 
florbetaben (18F) in patients with Alzheim-
er’s disease and healthy controls: a multicen-
tre phase 2 diagnostic study. Lancet Neurol 
2011;10:424–435.
17 Barthel H, Luthardt J, Becker G, Patt M, 
Hammerstein E, Hartwig K, Eggers B, Sattler 
B, Schildan A, Hesse S, Meyer PM, Wolf H, 
Zimmermann T, Reischl J, Rohde B, Gertz 
HJ, Reininger C, Sabri O: Individualized 
quantification of brain beta-amyloid bur-
den: results of a proof of mechanism phase 
0 florbetaben PET trial in patients with Al-
zheimer’s disease and healthy controls. Eur 
J Nucl Med Mol Imaging DOI: 10.1007/
s00259-011-1821-1.
18 Kornhuber J, Schmidtke K, Frolich L, Per-
neczky R, Wolf S, Hampel H, Jessen F, Heu-
ser I, Peters O, Weih M, Jahn H, Luckhaus 
C, Hull M, Gertz HJ, Schroder J, Pantel J, 
Rienhoff O, Seuchter SA, Ruther E, Henn 
F, Maier W, Wiltfang J: Early and dif-
ferential diagnosis of dementia and mild 
cognitive impairment: design and cohort 
baseline characteristics of the German De-
mentia Competence Network. Dement Geriatr 
Cogn Disord 2009;27:404–417.
19 Leinonen V, Alafuzoff I, Aalto S, Suotunen T, 
Savolainen S, Nagren K, Tapiola T, Pirttila T, 
Rinne J, Jaaskelainen JE, Soininen H, Rinne 
JO: Assessment of beta-amyloid in a fron-
tal cortical brain biopsy specimen and by 
positron emission tomography with carbon 
11-labeled Pittsburgh compound B. Arch 
Neurol 2008;65:1304–1309.
20 Ikonomovic MD, Klunk WE, Abraham-
son EE, Mathis CA, Price JC, Tsopelas ND, 
Lopresti BJ, Ziolko S, Bi W, Paljug WR, Deb-
nath ML, Hope CE, Isanski BA, Hamilton 
RL, DeKosky ST: Post-mortem correlates of 
in vivo PIB-PET amyloid imaging in a typical 
case of Alzheimer’s disease. Brain 2008;131:
1630–1645.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
21
/2
01
6 
5:
51
:1
7 
PM
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
Erratum
Figure 2 of the article ‘Impact of Beta-Amyloid-Specific Florbetaben PET Im-
aging on Confidence in Early Diagnosis of Alzheimer’s Disease’ by Schipke et 
al. [Dement Geriatr Cogn Disord 2012; 33: 416–422 (DOI: 10.1159/000339367)] 
has been published with an error. Please see below the correct figure:
© 2012 S. Karger AG, Basel
Accessible online at:
www.karger.com/dem
22
(100%)
22
Negative
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99
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20
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Confidence unchanged
Fig. 2. Frequency and direction of change of confidence in the 
initial diagnosis on receiving the result of the florbetaben PET 
scan. Numbers are given for the 121 probable AD patients.
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